Skip to content

Chemotherapy

Page 1 of 1

"Even though we can cure a large subset of children with T-ALL, about 25 percent of pediatric patients with the disease die of it, either because first-line chemotherapy fails, or because they relapse after being in remission for a year or two. Until now, there has been no way of determining ahead of time whether a patient is likely to be helped by the standard regimen of front-line drugs," said the study's lead author, Alejandro Gutierrez, a Harvard Medical School instructor in pediatrics at Dana-Farber.

Better odds

New test could predict best treatment for children with leukemia

Health|

Date

 Shiladitya Sengupta, an assistant professor at Harvard Medical School, has led an effort to devise a way to keep platinum atoms,  useful in a drug to combat tumors, from hurting healthy tissues.

Improving a cancer drug

Nanotechnology creates delivery system in animals that allows researchers to target tumors while sparing kidneys

Health|

Date